# Rheo-Erythrocrine Dysfunction as a Biomarker for RIC Treatment in Acute Ischemic Stroke

> **NCT04266639** · NA · COMPLETED · sponsor: **Grethe Andersen** · enrollment: 45 (actual)

## Conditions studied

- Stroke, Acute
- Ischemic Stroke
- Cerebrovascular Disorders
- Central Nervous System Diseases

## Interventions

- **DEVICE:** Remote Ischemic Conditioning
- **DEVICE:** Sham Remote Ischemic Conditioning

## Key facts

- **NCT ID:** NCT04266639
- **Lead sponsor:** Grethe Andersen
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-29
- **Primary completion:** 2021-07-31
- **Final completion:** 2021-07-31
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2022-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04266639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04266639, "Rheo-Erythrocrine Dysfunction as a Biomarker for RIC Treatment in Acute Ischemic Stroke". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT04266639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*